King Pharmaceuticals Announces ALTACE(R) Tablets Launch

February 19, 2008 – 7:38 am | posted in Hypertension

King Pharmaceuticals, Inc. (NYSE: KG) announced the launch of its new ALTACE(R) Tablets (ramipril). King has received orders and initiated shipments of ALTACE(R) Tablets to many of its customers. The Company will continue to make available ALTACE(R) Capsules (ramipril).

About ALTACE

ALTACE is the leading branded ACE inhibitor with multiple indications. ALTACE is indicated for the treatment of hypertension. ALTACE has also been shown to reduce the risk of death in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Based upon the results of the landmark HOPE trial, ALTACE 10mg is also indicated in patients age 55 or over at high risk of developing a major CV event either because of a history of coronary artery disease, stroke or peripheral vascular disease or because of diabetes that is accompanied by at least one other CV risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of stroke, myocardial infarction, or death from CV causes. ALTACE can be used in addition to other needed treatments (such as antihypertensive, antiplatelet or lipid-lowering therapies).

ALTACE should not be taken during pregnancy, as death or injury to an unborn child may result, or if serious side effects related to previous ACE inhibitors have occurred. Prescription ALTACE is not for everyone. ALTACE may cause swelling of the mouth, tongue, or throat, which could cause extremely serious risk and requires immediate medical care. ALTACE may lower blood sugar if taken for diabetes. A physician should be contacted if one experiences symptoms of low blood sugar such as sweating or shakiness. Common side effects include persistent dry cough, dizziness, and light-headedness due to low blood pressure.

About King Pharmaceuticals

King, headquartered in Bristol, Tenn., is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

King Pharmaceuticals

ShareThis

Tags: , , , , , , , ,

Also Read

  • Mylan Announces Final FDA Approval For Finasteride Tablets USP, 5mg
  • King Pharmaceuticals And Palatin Technologies Delay Immediate Plans For Phase 3 Clinical Program With Bremelanotide For Erectile Dysfunction
  • Lupin Pharmaceuticals, Inc. Announces Tentative Approval Of Trandolapril Tablets
  • Lupin Pharmaceuticals Announces Tentative Approval Of Generic ZOLOFT(R)
  • Boca Pharmacal Receives FDA Approval For Generic Pamine(R) And Pamine(R) Forte Tablets
  • Ranbaxy Receives Tentative Approval For Valsartan Tablets
  • Swaziland’s King ‘Sets Poor Example’ For Country Deeply Affected By HIV/AIDS, Article Says
  • Ranbaxy Is Granted Final Approval To Manufacture And Market Cefprozil Anti- Infective Tablets
  • Caraco Pharmaceutical Laboratories Ltd. Announces FDA Approval To Market Generic Ambien(R)
  • Unilever Recalls Pot Noodle Batches, UK

    • You must be logged in to post a comment.